Iniciar sesión Regístrese gratis

Kazia Therapeutics EPS

¿Qué es el EPS de Kazia Therapeutics?

El EPS de Kazia Therapeutics Limited es -0.14

¿Cuál es la definición de EPS?



Las ganancias por acción (EPS) son la parte de las ganancias de una empresa asignada a cada acción en circulación de acciones ordinarias. Se ajusta para la dilución y se calcula a lo largo de doce meses.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS de compañías en Sector Health Care en ASX en comparadas con Kazia Therapeutics

¿Qué hace Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Empresas con eps similar a Kazia Therapeutics